Healthcare >> Analyst Interviews >> May 20, 2002

Genomics & Gene-based Therapeutics: Albert Rauch – Ladenburg Thalmann & Co

ALBERT RAUCH is an Analyst and head of healthcare equity research at Ladenburg, Thalmann & Co., focusing on genomic, gene therapy and protein synthesis stocks. He was previously with Wachovia (formerly First Union), EVEREN Securities and A.G. Edwards. Prior to becoming an Equity Research Analyst, Mr. Rauch was a Senior Research Scientist with Pfizer and taught at the Wake Forest University School of Medicine. A Chartered Financial Analyst, he received a BS and an MS from the University of South Dakota, an MBA from Rensselaer Polytechnic Institute and a PhD from Emory University. Profile
TWST: Will you begin by telling us about the sector that you

cover for Ladenburg Thalmann?

Mr. Rauch: I focus on genomics, antibody therapeutics, and gene

therapy companies in the